Abstract: AIM: To evaluate the efficacy and safety of Lipo-prostaglandin E₁ on treating diabetic peripheral neuropathy(DPN) Lipo-prostaglandin E₁.METHODS: The electronic databases OVID-LWW,CNKI and Wanfang were searched to collect randomized controlled trials(RCT) by interventions of Lipo prostaglandin E₁ for the treatment of DPN. The methodological quality of the trials were evaluated and the valid data for Meta-analysis were extracted.RESULTS: 11 RCT and 978 patients were included. Test group was treated combined with common integrated Lipo prostaglandin E₁,or combined treatment on the basis of combined therapy plus B vitamins. Meta analysis showed that the prostaglandin E₁ group of patients with DPN is better than the control group in improving nerve conduction velocity. After treatment, the WMD of the median nerve motor conduction velocity (MCV) and common peroneal nerve MCV and their 95% CI were 4.39(2.86, 5.91) and 3.38(2.21,4.54). The median nerve sensory nerves conduction velocity (SCV) sensitivity analysis of the WMD and 95% CI were 3.55(1.86,5.24).CONCLUSION: Lipo-prostaglandin E₁ can improve nerve conduction velocity in patients with DPN. However, due to the low quality of research literature, more scientific and standardized, high quality, large sample, long-term follow-up of the RCT are still needed.

Key words: Lipo-prostaglandin E₁, Diabetic neuropathy, Meta analysis